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ABSTRACT
The CDK inhibitor SNS-032 had previously exerted promising anti-neuroblastoma 
DFWLYLW\ YLD &'. DQG  LQKLELWLRQ $%&% H[SUHVVLRQ ZDV LGHQWL¿HG DV PDMRU
determinant of SNS-032 resistance. Here, we investigated the role of ABCB1 in 
acquired SNS-032 resistance. In contrast to ABCB1-expressing UKF-NB-3 sub-
lines resistant to other ABCB1 substrates, SNS-032-adapted UKF-NB-3 (UKF-NB-
3rSNS- 032300nM) cells remained sensitive to the non-ABCB1 substrate cisplatin and 
were completely re-sensitized to cytotoxic ABCB1 substrates by ABCB1 inhibition. 
Moreover, UKF-NB-3rSNS-032300nM cells remained similarly sensitive to CDK7 and 9 
inhibition as UKF-NB-3 cells. In contrast, SHEPrSNS-0322000nM, the SNS-032-resistant 
sub-line of the neuroblastoma cell line SHEP, displayed low level SNS-032 resistance 
also when ABCB1 was inhibited. This discrepancy may be explained by the higher 
SNS-032 concentrations that were used to establish SHEPrSNS-0322000nM cells, 
since SHEP cells intrinsically express ABCB1 and are less sensitive to SNS-032 (IC
50
 
912 nM) than UKF-NB-3 cells (IC
50
 153 nM). In conclusion, we show that ABCB1 
expression represents the primary (sometimes exclusive) resistance mechanism in 




Neuroblastoma is the most frequent solid 
extracranial pediatric cancer. About half of the patients are 
diagnosed with high-risk disease associated with overall 
survival rates below 50% despite myeloablative therapy 
and differentiation therapy using retinoids [1, 2].
SNS-032 (BMS-387032) is a cyclin-dependent 
kinase 2 (CDK2), 7, and 9 inhibitor under pre-clinical 
and clinical investigation for a wide range of solid 
and hematologic malignancies [316] including 
neuroblastoma [1719]. The compound was initially 
introduced as N-acyl-2-aminothiazole inhibitor of CDK2 
[3]. The relevance of CDK2, CDK7, and/ or CDK9 as 
crucial SNS-032 drug targets differs between different 
cancer cell types [4, 79, 12, 19]. We recently showed 
that therapeutic SNS-032 concentrations exerted anti-
neuroblastoma effects in a panel of 109 neuroblastoma 
cell lines (19 parental neuroblastoma cell lines, 90 sub-
lines with acquired resistance to 14 different anti-cancer 
drugs) and in primary neuroblastoma cells [19]. SNS-
032 further inhibited tumor growth in a chemoresistant 
neuroblastoma xenograft model [19]. Interference with 
CDK7 and CDK9 appeared to be critical for the anti-
neuroblastoma effects of SNS-032 [19].
SNS-032 had further been speculated to interfere 
with ABCB1 (also known as P-glycoprotein or MDR1) 
[20]. Our report (published on the 1st December 2013) 
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[19] and another report (published on 23rd December 
>@FRQ¿UPHGWKLVDVVXPSWLRQ$%&%H[SUHVVLRQ
was the dominant SNS-032-resistance mechanism in 
neuroblastoma cells from a panel of 109 neuroblastoma 
cell lines [19]. Only ABCB1-expressing neuroblastoma 
cell lines were insensitive to therapeutically achievable 
SNS-032 concentrations. In the presence of ABCB1 
inhibitors, all 30 ABCB1-expressing neuroblastoma 
cell lines displayed SNS-032 IC
50
 values in the range of 
therapeutic SNS-032 concentrations [19].
Here, we established and characterized SNS-032-
UHVLVWDQW VXEOLQHV RI WKH 0<&1DPSOL¿HG $%&%
negative neuroblastoma cell line UKF-NB-3 (UKF-
NB-3rSNS-032300nM DQG WKH QRQ0<&1DPSOL¿HG
ABCB1-expressing neuroblastoma cell line SHEP 
(SHEPrSNS-0322000nM) to analyze the role of ABCB1 in 
neuroblastoma models of acquired SNS-032 resistance.
RESULTS
Enhanced ABCB1 expression in the SNS-032-
resistant UKF-NB-3 sub-line UKF-NB-3rSNS-
032300nM
UKF-NB-3 cells were adapted to growth in the 
presence of SNS-032 300 nM by step-wise increase of 
the SNS-032 concentration. No pre-existing resistant 
sub-population could be selected by directly applying 
SNS-032 300 nM. The SNS-032 IC
50
 value was four times 
higher in SNS-032-adapted UKF-NB-3rSNS-032300nM 
cells (606.7 nM) than in UKF-NB-3 cells (152.6 nM). 
UKF-NB-3 and its SNS-032-resistant sub-line UKF-NB-
3rSNS-032300nM were characterized by similar doubling 
times (UKF-NB-3: 26.6 ± 8.2 h, UKF-NB-3rSNS-032300nM 
32.9 ± 12.8 h) and a similar morphology (Supplementary 
Figure S1). However, UKF-NB-3rSNS-032300nM cells 
displayed elevated ABCB1 levels relative to UKF-NB-3 
cells (Figure 1, Supplementary Figure S2). We had 
previously shown that SNS-032 is also a substrate 
of ABCG2 (also known as BCRP) [19]. In contrast, 
expression of ABCC1 (also known as MRP1), another 
relevant ABC transporter known to be involved in cancer 
cell drug resistance in various cancer entities including 
QHXUREODVWRPD>@GLGQRWLQÀXHQFHDQWLFDQFHUDFWLYLW\RI
SNS-032 (Supplementary Figure S3). We did neither detect 
increased ABCG2 nor ABCC1 expression in UKF-NB-
3rSNS-032300nM cells (Figure 1, Supplementary Figure S2). 
Sensitization of ABCB1-expressing drug-
resistant UKF-NB-3 sub-lines to SNS-032 and 
other ABCB1 substrates by inhibition of ABCB1
UKF-NB-3rSNS-032300nM cells displayed 
cross-resistance to the cytotoxic ABCB1 substrates 
doxorubicin, etoposide, and vincristine (Figure 2, 
Supplementary Table S1A). The fold changes IC
50
 
resistant UKF-NB-3rSNS-032300nM / IC
50
 UKF-NB-3 
ranged between 2.0 (etoposide) and 10.8 (vincristine) 
(Figure 3, Supplementary Table S1A). Addition of 
verapamil 10 µM, a concentration that did not affect the 
viability of the investigated cell lines (Supplementary 
Table S1A), re-sensitized UKF-NB-3rSNS-032300nM to 
SNS-032 to the level of the parental UKF-NB-3 cells 
as indicated by a fold change IC
50
 SNS-032 in UKF-
NB-3rSNS-032300nM cells in the presence of verapamil/ 
IC
50
 SNS-032 in UKF-NB-3 cells below 2 (Figure 3, 
Supplementary Table S1A). Verapamil also reduced the 
doxorubicin, etoposide, and vincristine IC
50
 values in 
UKF-NB-3rSNS-032300nM cells to a level similar to UKF-
NB-3 (Figure 3; Supplementary Table S1A).
7RIXUWKHUFRQ¿UPWKHUROHRI$%&%LQ8.)1%
3rSNS-032300nM cells, we depleted ABCB1 using siRNA. 
ABCB1 depletion increased SNS-032 sensitivity in UKF-
NB-3rSNS-032300nM cells. Since no complete suppression 
of ABCB1 expression was achieved by siRNA, the 
SNS-032 IC
50
 remained higher than in parental UKF-
NB-3 cells (Supplementary Table S1B; Supplementary 
Figure S4). However, the SNS-032 IC
50
 value could be 
reduced in UKF-NB-3rSNS-032300nM cells to the level of 
UKF-NB-3 cells by the use of zosuquidar (Supplementary 
Table S1C), an alternative ABCB1 inhibitor that 
structurally differs from verapamil [23].
0RUHRYHU ZH V\QWKHVL]HG D ÀXRUHVFHQW 616
032-BODIPY derivative. Flow cytometry experiments 
indicated, compared to UKF-NB-3, a reduced 
accumulation of SNS-032-BODIPY in ABCB1-transduced 
UKF-NB-3 (UKF-NB-3ABCB1) cells and UKF-NB-
3rSNS-032300nM cells that could be restored by the use 
of verapamil (Supplementary Figure S5). Notably, the 
differences between SNS-032-BODIPY accumulation 
in UKF-NB-3rSNS-032300nM cells in the absence or 
presence of verapamil seemed to be small compared to the 




 values (UKF-NB-3rSNS-032300nM: 607 nM; 
UKF-NB-3ABCB1: 3885 nM).
The doxorubicin-resistant (UKF-NB-3rDOX20), 
etoposide-resistant (UKF-NB-3rETO100), and vincristine-
resistant (UKF-NB-3rVCR10) UKF-NB-3 sub-lines that 
express ABCB1 displayed cross-resistance to SNS-032, 
doxorubicin, etoposide, and vincristine. Verapamil 
decreased the SNS-032 IC
50
 values in all three cell 
lines to a level similar to UKF-NB-3 as indicated by 
fold changes (SNS-032 IC
50
 in resistant cell lines in the 
presence of verapamil/ SNS-032 IC
50
 in UKF-NB-3 cells) 
below 2 (Figure 3, Supplementary Table S1A). However, 
verapamil did not re-sensitize UKF-NB-3rDOX20, UKF-
NB-3rETO100, or UKF-NB-3rVCR10 cells to doxorubicin, 
etoposide, or vincristine to the level of UKF-NB-3 cells 
(Figure 3, Supplementary Table S1A). The only exemption 
was the vincristine sensitivity of UKF-NB-3rETO100 cells 
(Figure 3, Supplementary Table S1A).
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Cross-resistance of ABCB1-expressing drug-
resistant UKF-NB-3 sub-lines to the non-ABCB1 
substrate cisplatin and of the cisplatin-resistant 
UKF-NB-3 sub-line UKF-NB-3rCDDP1000 to 
ABCB1 substrates
:HQH[WGHWHUPLQHGWKHUHVLVWDQFHSUR¿OHWRFLVSODWLQ
that is not an ABCB1 substrate. UKF-NB-3rSNS-032300nM 
and UKF-NB-3rETO100 did not display cisplatin resistance 
(cisplatin IC
50
 resistant UKF-NB-3 sub-line/ cisplatin IC
50
 
UKF-NB-3 < 2). In contrast, UKF-NB-3rDOX20 and UKF-
NB-3rVCR10 cells were substantially less sensitive to cisplatin 
than UKF-NB-3 cells (Figure 4A; Supplementary Table S1D). 
UKF-NB-3rCDDP1000 cells displayed profound 
cisplatin resistance (cisplatin IC
50
: UKF-NB-3, 280 nM; 
UKF-NB-3rCDDP1000, 8936 nM, Supplementary Table S1D) 





 8.)1%   WR GR[RUXELFLQ IROG
change 4.0) and vincristine (fold change 3.3) but not to 
SNS-032 (fold change 0.8) or etoposide (fold change 1.6) 
(Figure 4B, Supplementary Table S1E).
CDK7 and CDK9 as drug targets in UKF-NB-
3rSNS-032300nM cells
We had previously shown that SNS-032 reduces the 
viability of UKF-NB-3 cells via interference with CDK7 
and CDK9 and subsequent RNA polymerase II inhibition 
resulting in depletion of anti-apoptotic proteins with a high 
turnover rate including Mcl-1, XIAP, and survivin [19].
In the presence of verapamil 10 µM, SNS-032 300 nM 
exerted similar effects on RNA polymerase II protein 
levels, RNA polymerase II phosphorylation at Ser-5 (target 
of CDK7), RNA polymerase II phosphorylation at Ser-2 
(target of CDK9) (Figure 5A), RNA polymerase II activity 
(Figure 5B), and XIAP, Mcl-1, and survivin protein levels 
(Figure 5A) in UKF-NB-3rSNS-032300nM cells as in UKF-
NB-3 cells.





 8.)1% ZHUH   IRU
the CDK2, 7, and 9 inhibitor seliciclib (also known 
as roscovitine or CYC202) [24], the CDK9 inhibitor 
LDC000067 [25], the CDK7 inhibitor BS-181 [26], and 
Figure 1: ABC transporter expression levels in in the neuroblastoma cell lines UKF-NB-3 and SHEP and their sub-
lines with acquired resistance to SNS-032 resistance (UKF-NB-3rSNS-032300nM, SHEPrSNS-0322000nM). (A) Cropped 
representative Western blots indicating ABCB1, ABCG2, and ABCC1 levels. (B$%&%$%&*DQG$%&&OHYHOVGHWHFWHGE\ÀRZ
F\WRPHWU\DQGSUHVHQWHGDVUHODWLYHÀXRUHVFHQFHXQLWVUIX5HSUHVHQWDWLYHÀRZF\WRPHWU\KLVWRJUDPVDUHSUHVHQWHGLQ6XSSOHPHQWDU\
Figure S2. * P < 0.05 relative to UKF-NB-3 cells, # P < 0.05 relative to SHEP. Positive controls were ABCB1-transduced UKF-NB-3 cells 
for ABCB1, ABCG2-transduced UKF-NB-3 cells for ABCG2, and NLFrVCR10 cells for ABCC1.
Oncotarget58054www.impactjournals.com/oncotarget
the CDK 1, 2, 4, 6, 7, and 9 inhibitor alvocidib (also 
NQRZQDVÀDYRSLULGRORU+05>@)LJXUH$
Supplementary Table S1F). Finally, UKF-NB-3rSNS-
032300nM cells were similar sensitive to siRNA-mediated 
depletion of CDK7 and CDK9 as UKF-NB-3 cells 
(Figure 6B, Supplementary Table S1G). Hence, UKF-
NB-3rSNS-032300nM cells do not seem to have acquired 
VSHFL¿FUHVLVWDQFHWR&'.LQKLELWLRQ
Investigation of SHEPrSNS-0322000nM, a SNS-032-
resistant sub-line of the neuroblastoma cell line 
SHEP
In order to investigate to which extent ABCB1 
expression may be a resistance mechanism in an 
additional model of acquired SNS-032 resistance, 
we established an SNS-032-resistant SHEP sub-line 
(SHEPrSNS-0322000nM). In contrast to the MYCN-
amplified neuroblastoma cell line UKF-NB-3, SHEP 
cells do not harbor a MYCN amplification. Also in 
contrast to UKF-NB-3, SHEP cells express ABCB1 
and display a higher SNS-032 IC
50
 value than UKF-
NB-3 cells (SHEP 912 nM; UKF-NB-3 153 nM 
(Supplementary Table S1A, S1H)). SHEP cells 
were adapted to growth in the presence of SNS-
032 2000 nM by step-wise increase of the SNS-032 
concentration. No pre-existing SNS-032-resistant 
sub-population could be selected by directly applying 
SNS-032 2000 nM.
SHEP and SHEPrSNS-0322000nM cells displayed 
similar doubling times (SHEP: 17.9 ± 1.4 h, SHEPrSNS-
0322000nM 17.9 ± 0.6 h) and a similar morphology 
Figure 2: Sensitivity of UKF-NB-3 and its ABCB1-expressing sub-lines with acquired resistance to SNS-032 (UKF-NB-
3rSNS-032300nM), doxorubicin (UKF-NB-3rDOX20), etoposide (UKF-NB-3rETO100), and vincristine (UKF-NB-3rVCR10) 
to the cytotoxic ABCB1 substrates SNS-032, doxorubicin, etoposide, and vincristine in the absence or presence of the 
ABCB1 inhibitor verapamil. 9HUDSDPLODORQHGLGQRWLQÀXHQFHFHOOYLDELOLW\6XSSOHPHQWDU\7DEOH6$P < 0.05 relative to the 
drug concentration that reduces cell viability by 50% (IC
50
) in UKF-NB-3 cells.
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(Supplementary Figure S1). Adaptation of SHEP cells 
to SNS-032 resulted in a further increase of the cellular 
ABCB1 levels but did not affect ABCG2 or ABCC1 
expression levels (Figure 1, Supplementary Figure S2).
Similar to UKF-NB-3rSNS-032300nM cells, (cross-)
resistances predominantly depended on ABCB1 function 
in SHEPrSNS-0322000nM cells (Figure 7 and Figure 8A, 
Supplementary Table S1H and Supplementary Table S1I). 
ABCB1 inhibition using verapamil did not always reduce the 
IC
50
 values for the ABCB1 substrates to the level of parental 





 SHEP in the presence of 
verapamil was close to 2 for SNS-032 (1.98) and doxorubicin 
(1.96) and above 2 for etoposide (2.87), while it was 1.45 
for vincristine (Figure 7, Supplementary Table S1H). For 
the non-ABCB1 substrate cisplatin and the CDK inhibitors 





 SHEP were clearly 
below 2 (Figure 8A, Supplementary Table S1I).
In the presence of verapamil, SNS-032 600 
nM caused maximum RNA polymerase inhibition in 
SHEPrSNS-0322000nM cells (32 ± 4% activity relative 
to non-treated control). This effect was not further 
enhanced by increasing the SNS-032 concentration 
to 1200 nM (31 ± 5% activity relative to non-treated 
control) (Figure 8B, Supplementary Table S1J). 
In contrast to this, combined SHEP cell treatment 
with SNS-032 600 nM and verapamil reduced RNA 
polymerase activity to 22 ± 3% relative to untreated 
control, which was further decreased by combined 
SNS-032 1200 nM and verapamil treatment to 
16 ± 3% (Figure 8B, Supplementary Table S1J). 
Figure 3: Relative sensitivity of UKF-NB-3 and its ABCB1-expressing sub-lines with acquired resistance to SNS-032 
(UKF-NB-3rSNS-032300nM), doxorubicin (UKF-NB-3rDOX20), etoposide (UKF-NB-3rETO100), and vincristine (UKF-
NB-3rVCR10) to the cytotoxic ABCB1 substrates SNS-032, doxorubicin, etoposide, and vincristine in the absence or 
presence of the ABCB1 inhibitor verapamil. (A) Fold change IC
50
 investigated cell line/ IC
50
 UKF-NB-3; (B) Fold change IC
50
 




The positive control actinomycin D 100 ng/mL, which 
is also an ABCB1 substrate [28] and interferes with 
RNA polymerase activity through DNA intercalation 
independently of CDK7 and CDK9 [29, 30], exerted 
the same activity in SHEP cells (19.1 ± 2.9% relative to 
untreated control) and SHEPrSNS-0322000nM cells (19.5 
± 2.8% relative to untreated control) in the presence 
of verapamil (Figure 8B, Supplementary Table S1J). 
These findings suggest that SHEPrSNS-0322000nM cells 
have developed mechanisms to specifically compensate 
SNS-032-mediated CDK7- and CDK9 inhibition.
DISCUSSION
To study acquired SNS-032 resistance mechanisms, 
we established two SNS-032-resistant neuroblastoma cell 
lines. Elevated ABCB1 expression represented, depending 
on the investigated cell line model, a dominant or even 
exclusive acquired SNS-032 resistance mechanism. 
In the clinics, few neuroblastomas appear to express 
ABCB1 at diagnosis [31]. However, ABCB1 expression 
might represent an acquired resistance mechanism in 
neuroblastoma [32]. In addition, ABCB1 expression may 
be an SNS-032-associated acquired resistance mechanism 
in neuroblastoma. Drug-adapted cancer cell lines were 
previously successfully used to identify novel clinically 
relevant acquired drug resistance mechanisms [3337]. 
The resistance status of the SNS-032-resistant 
UKF-NB-3 sub-line UKF-NB-3rSNS-032300nM depended 
exclusively on ABCB1 function. ABCB1 inhibition 
completely re-sensitized UKF-NB-3rSNS-032300nM to 
SNS-032 to the level of UKF-NB-3 cells. The same 
observation was made for UKF-NB-3rSNS-032300nM 
cell sensitivity to the ABCB1 substrates doxorubicin, 
etoposide, and vincristine. UKF-NB-3rSNS-032300nM 
cells displayed cross-resistance to these agents but 
their sensitivity to these drugs returned to the levels of 
UKF-NB-3 in the presence of the ABCB1 inhibitor 
verapamil. Moreover, UKF-NB-3rSNS-032300nM cells did 
not display cross-resistance to the non-ABCB1 substrate 
cisplatin or the alternative CDK inhibitors seliciclib, 
LDC000067, BS-181, or alvocidib. Previous results 
had demonstrated that SNS-032 reduces the viability of 
UKF-NB-3 cells (and other cancer cells) via interference 
with CDK7 and CDK9 and subsequent RNA polymerase 
II inhibition resulting in depletion of anti-apoptotic 
proteins with a high turnover rate including Mcl-1, XIAP, 
and survivin [7 ,8, 19]. In the presence of the ABCB1 
Figure 4: Sensitivity of UKF-NB-3 and its ABCB1-expressing sub-lines with acquired resistance to SNS-032 (UKF-NB-
3rSNS-032300nM), doxorubicin (UKF-NB-3rDOX20), etoposide (UKF-NB-3rETO100), and vincristine (UKF-NB-3rVCR10) 
to the non-ABCB1 substrate cisplatin, and sensitivity of the non ABCB1-expressing cisplatin-resistant UKF-NB-3 
sub-line UKF-NB-3rCDDP1000 to the ABCB1 substrates SNS-032, doxorubicin, etoposide, and vincristine. (A) Cisplatin 
concentrations that reduce cell viability by 50% (IC
50
) and relative cisplatin sensitivity in drug-resistant UKF-NB-3 sub-lines relative 
to UKF-NB-3, numerical values are presented in Supplementary Table S1D. *P < 0.05 relative to UKF-NB-3; (B) IC
50
 values for SNS-
032, doxorubicin, etoposide, or vincristine in UKF-NB-3 or UKF-NB-3rCDDP1000 cells, numerical values are presented in Supplementary 
Table S1E. *P < 0.05 relative to UKF-NB-3.
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inhibitor verapamil, SNS-032 exerted similar effects on 
CDK7, CDK9, and RNA polymerase II activity as well 
as on the cellular levels of Mcl-1, XIAP, and survivin 
in UKF-NB-3rSNS-032300nM and in UKF-NB-3 cells. 
Moreover, UKF-NB-3rSNS-032300nM and UKF-NB-3 
cells did not differ in their sensitivity to siRNA-mediated 
depletion of CDK7 and CDK9. Taken together, these 
¿QGLQJVGHPRQVWUDWHWKDW$%&%H[SUHVVLRQUHSUHVHQWV
an exclusive resistance mechanism in UKF-NB-3rSNS-
032300nM cells.
ABCB1 expression as sole resistance mechanism is 
unusual even among UKF-NB-3 sub-lines with acquired 
resistance to ABCB1 substrates. The ABCB1-expressing 
drug-resistant UKF-NB-3 sub-lines UKF-NB-3rDOX20, 
UKF-NB-3rETO100, and UKF-NB-3rVCR10 maintained 
a substantial level of resistance to the respective drug of 
adaptation even when ABCB1 was inhibited. In addition, 
UKF-NB-3rDOX20 and UKF-NB-3rVCR10 cells were 
(in contrast to UKF-NB-3rSNS-032300nM cells) less 
sensitive to the non-ABCB1 substrate cisplatin than UKF-
1% FHOOV7KHVH ¿QGLQJV GHPRQVWUDWH WKDW 8.)1%
3rDOX20, UKF-NB-3rVCR10, and UKF-NB-3rETO100 cells 
have developed further resistance mechanisms in addition 
to increased ABCB1 expression.
The investigation of the second SNS-032-resistant 
neuroblastoma cell line SHEPrSNS-0322000nM resulted 
in slight but noticeable differences. We had selected the 
neuroblastoma cell line SHEP as additional model for 
our study because it differs in two crucial parameters 
from UKF-NB-3: 1) SHEP cells do not harbor a MYCN 
Figure 5: Effects of SNS-032 on CDK7 and CDK9 signalling and RNA polymerase activity in UKF-NB-3 and UKF-
NB-3rSNS-032300nM cells in the absence or presence of the ABCB1 inhibitor verapamil. (A) Cropped Western blots indicating 
RNA polymerase II protein levels, RNA polymerase II phosphorylation at Ser-5 (target of CDK7), RNA polymerase II phosphorylation at 
Ser-2 (target of CDK9), and levels of anti-apoptotic proteins with a high rate (XIAP, Mcl-1, survivin) in UKF-NB-3 and UKF-NB-3rSNS-
032300nM cells after 24 h of incubation. ȕ-actin served as loading control. (B) Effects of SNS-032 on the RNA polymerase activity in UKF-
NB-3 and UKF-NB-3rSNS-032300nM cells in the absence or presence of the ABCB1 inhibitor verapamil after 6 h of incubation. Actinomycin 
D 100 ng/mL served as positive control. *P < 0.05 relative to non-treated control.
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DPSOL¿FDWLRQDPDMRUPDUNHURIKLJKULVNQHXUREODVWRPD
[1 ,2], and 2) SHEP cells are characterized by intrinsic 
ABCB1 expression. SHEPrSNS-0322000nM cells retained 
some low-level resistance to SNS-032 and doxorubicin 
(about 2-fold decreased sensitivity compared to SHEP) and 
some more pronounced resistance to etoposide (2.9-fold 
relative to SHEP) also in the presence of verapamil. This 
demonstrates that SHEPrSNS-0322000nM cells have acquired 
other resistance mechanisms in addition to ABCB1 
expression. SNS-032 also exerted decreased effects on 
RNA polymerase activity in SHEPrSNS-0322000nM cells than 
in SHEP cells when ABCB1 was inhibited. However, both 
cell lines displayed in the presence of the ABCB1 inhibitor 
verapamil the same sensitivity to RNA polymerase 
inhibition by actinomycin D that is also an ABCB1 
substrate [28] and interferes with RNA polymerase activity 
by CDK7- and CDK9-independent mechanisms [29, 
@7KHVH¿QGLQJVDUHDJDLQLQFRQWUDVWWRREVHUYDWLRQV
in UKF-NB-3rSNS-032300nM cells and indicate that 
SHEPrSNS-0322000nM cells developed mechanisms to bypass 
SNS-032-induced CDK7 and 9 inhibition and subsequent 
RNA polymerase activity but no general resistance to 
51$ SRO\PHUDVH LQKLELWLRQ 7KLV VSHFL¿F UHVLVWDQFH WR
RNA polymerase inhibition via interference with CDK7 
DQGDOVRFRQ¿UPV&'.DQGDVFULWLFDOGUXJWDUJHWVRI
SNS-032 in neuroblastoma that was previously suggested 
[19]. Hence, drug-adapted cells can be used to identify and 
FRQ¿UPGUXJPHFKDQLVPVRIDFWLRQ
 A likely explanation for the differences observed 
between the resistance phenotypes of UKF-NB-
3rSNS-032300nM and SHEPrSNS-0322000nM cells is that 
SHEPrSNS-0322000nM cells were adapted to higher SNS-
032 concentrations. While non-ABCB1 expressing UKF-
NB-3 cells are highly sensitive to SNS-032 (IC
50
 153 nM), 
ABCB1-expressing SHEP cells display an IC
50
 value of 
912 nM, which is above the therapeutically achievable 
SNS-032 plasma concentration of 754 nM [14]. Therefore, 
SHEP cells were adapted to growth in the presence of a 
much higher SNS-032 concentration (2000 nM) than 
UKF-NB-3 cells (300 nM). The SNS-032 IC
50
 of UKF-
NB-3rSNS-032300nM cells (607 nM) remained below the 
SNS-032 IC
50
 of parental SHEP cells, whereas the SNS-
032 IC
50
 of SHEPrSNS-0322000nM cells (5045 nM) was 
about 8-fold higher than that of UKF-NB-3rSNS-032300nM 
cells. Thus, it does not appear implausible that UKF-NB-
3rSNS-032300nM cells might develop additional resistance 
mechanisms if they were further adapted to higher SNS-
032 concentrations. 
It remains unclear why SHEPrSNS-0322000nM cells 
did not display cross-resistance to the other CDK inhibitors 
investigated. It is known that kinase inhibitors designed to 
interfere with the same or similar targets may substantially 
GLIIHU LQ WKHLU RYHUDOO SKDUPDFRORJLFDO SUR¿OHV ZLWK
regards to kinase inhibition as well as other structures) [8, 
10, 3842]. Hence, the lack of cross-resistance may not 
EHWRRVXUSULVLQJ7KHLQKLELWRU\SUR¿OHVRIWKHGLIIHUHQW
Figure 6: Sensitivity of UKF-NB-3 and its sub-line with acquired resistance to SNS-032 (UKF-NB-3rSNS-032300nM) to 
CDK inhibition by alternative inhibitors or by siRNA-mediated CDK depletion. (A) Relative sensitivity of UKF-NB-3 and 
UKF-NB-3rSNS-032300nM to the CDK2, 7, and 9 inhibitor seliciclib, the CDK7 inhibitor LDC000067, the CDK9 inhibitor BS-181, or the 
CDK 1,2,4,6,7, and 9 inhibitor alvocidib. Numerical values are presented in Supplementary Table S1F. (B) Effects of siRNA-mediated 
depletion of CDK7, CDK9, or CDK7 and CDK9 on UKF-NB-3 and UKF-NB-3rSNS-032300nM cell viability as determined by MTT assay 72 
h post-transfection. Non-targeting scrambled siRNA (scr siRNA) served as control. Western blots indicating siRNA-mediated effects on 
protein levels are presented in Supplementary Figure S6. Numerical values are presented in Supplementary Table S1G. * P < 0.05 relative 
to scr siRNA. 
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CDK inhibitors differ with regard to their CDK inhibitory 
SUR¿OHV6HOLFLFOLELQWHUIHUHVLQFRQWUDVWWR616ZLWK
CDK5 in addition to CDK2, CDK7, and CDK9 [24, 43]. 
BS-181 does in contrast to SNS-032 not inhibit CDK9 
[26]. LDC000067 was introduced as selective CDK9 
LQKLELWRUZLWKQHJOLJLEOHDI¿QLW\WRDOWHUQDWLYH&'.V>@
Alvocidib is a broad spectrum CDK inhibitor acting on 
CDKs 1, 2, 4, 6, 7, and 9 [27].
Notably, cisplatin-resistant (UKF-NB-3rCDDP1000), 
doxorubicin-resistant (UKF-NB-3rDOX20), and 
vincristine-resistant (UKF-NB-3rVCR10) UKF-NB-3 
sub-lines remained sensitive to seliciclib, LDC000067, 
BS-181, and alvocidib (Supplementary Table S1K) further 
supporting a possible role of CDKs as drug targets in 
neuroblastoma including therapy-refractory disease as 
previously suggested [1719]. The alvocidib IC
50
s were 
below 400 nM. In phase I clinical trials, steady-state 
plasma alvocidib concentrations > 400 µM were achieved 
in human patients [44].
In conclusion, we show that ABCB1 expression 
represents the predominant resistance mechanism 
in neuroblastoma cells with acquired resistance to 
SNS-032. Most strikingly (and in clear contrast to 
neuroblastoma cell lines with acquired resistance to 
other anti-cancer agents that are ABCB1 substrates), 
ABCB1 expression is an exclusive resistance mechanism 
Figure 7: Sensitivity of SHEP and its sub-line with acquired resistance to SNS-032 (SHEPrSNS-0322000nM) to the 
cytotoxic ABCB1 substrates SNS-032, doxorubicin, etoposide, and vincristine. (A) Concentrations that reduce cell viability 
by 50% (IC
50
LQWKHDEVHQFHRUSUHVHQFHRIWKH$%&%LQKLELWRUYHUDSDPLO9HUDSDPLODORQHGLGQRWLQÀXHQFHFHOOYLDELOLW\P < 0.05 
relative to the drug concentration that reduces cell viability by 50% (IC
50





SHEP in the absence or presence of verapamil. Numerical values are presented in Supplementary Table S1H.
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in UKF-NB-3rSNS-032300nM cells and a predominant 
resistance mechanism in SHEPrSNS-0322000nM cells. 
Although selective ABCB1 inhibitors are available 
[45, 46], clinical trials were disappointing. Reasons 
included that ABCB1 transporter inhibition may affect 
ABCB1-expressing hematopoietic stem cells and the 
body distribution of drugs due to effects on ABCB1 
present on tissue barriers (e.g. the blood-brain-barrier). 
Also cancer cells may express multiple ABC transporters 
[45, 46]. However, ABCB1 expression represents the 
dominant (sometimes exclusive) resistance mechanism 
to SNS-032 in neuroblastoma. Therefore, ABCB1 
inhibitors may be candidates for combination therapy 
ZLWK616WKDWLQFUHDVH616HI¿FDF\WKURXJK
(re)sensitization of ABCB1-expressing cancer cells, 
possibly reducing resistance formation.
MATERIALS AND METHODS
Drugs
SNS-032, BS-181, and LDC000067 were purchased 
from Selleck Chemicals via BIOZOL GmbH (Eching, 
Germany), seliciclib from LC Laboratories (Woburn, 
Figure 8: Sensitivity of SHEP and its sub-line with acquired resistance to SNS-032 (SHEPrSNS-0322000nM) to the non-
ABCB1 substrates cisplatin, seliciclib (CDK2, 7, and 9 inhibitor), LDC000067 (CDK7 inhibitor), and BS-181 (CDK9 




 SHEP; numerical values are presented in Supplementary Table S1K. (B) 
Effects of SNS-032 or actinomycin D (100 ng/mL) (interferes with RNA polymerase activity through DNA intercalation independently of 
CDK7 and CDK9) on RNA polymerase activity in SHEP and SHEPrSNS-0322000nM cells in the absence or presence of the ABCB1 inhibitor 
verapamil (10 µM) as determined after 6 h of incubation. Numerical values are presented in Supplementary Table S1J. * P < 0.05 relative 
to untreated control.
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Massachusetts), vincristine, cisplatin, and etoposide from 
TEVA GmbH (Radebeul, Germany), actinomycin D from 
Lundbeck Pharmaceuticals Ireland Limited (Dublin, 
Ireland), and verapamil from Sigma-Aldrich (Munich, 
Germany).
Synthesis and characterisation of SNS-032-
BODIPY
SNS-032-BODIPY was synthesized using SNS-032 
(Selleck Chemicals) and BDP-FL-NHS-ester (Lumiprobe, 
Hannover, Germany) (Supplementary Figure S7A). All 
other reagents and solvents were purchased from Fisher 
6FLHQWL¿F /RXJKERURXJK 8. 105 VSHFWUD ZHUH
collected on a JEOL 400 MHz. HRMS were collected on 
D %UXNHU 0LFUR72)4 VSHFWURPHWHU E\ GLUHFW LQMHFWLRQ
with a MeOH/HCOOH matrix. Excitation and emission 
spectra were collected on an Edinburgh Instruments FS-5 
VSHFWURÀXRULPHWHU +3/& WUDFHV ZHUH FROOHFWHG RQ D
Dionex U3000 HPLC apparatus.
To 7.68 mg (2.02 × 10-2 mmol) of SNS-032 
chloroform (1.3 mL) was added and the mixture sonicated 
until dossolution. BDP-FL NHS ester (purchased 
from Lumiprobe; 8.09 mg, 2.08 × 10-2 mmol) was also 
dissolved in chloroform (1.3mL) and sonicated to ensure 
dissolution. The SNS-032 mixture was added to BDP-
FL and the resulting sample was sonicated for 1 h. 
Reaction was monitored using thin-layer chromatography 
(dichloromethane: methanol  4:0.1; product rf: 0.21). 
5HDFWLRQ PL[WXUH ZDV FRQFHQWUDWHG DQG WKHQ SXUL¿HG
by preparative TLC using the above noted eluent. The 
adsorbed product band on the silica plate was scraped, 
isolated and rinsed repeatedly with acetonitrile to extract the 
product yielding 9.0 mg (1.38 × 10-2  mmol; 68%). Purity 
ZDVFRQ¿UPHGE\UHYHUVHSKDVH+3/&)LJXUH%±(
1H NMR (400 MHz, CDCl
3
): d 7.33 (s, 1H, Ar-H), 
7.13 (s, 1H, Ar-H), 6.93 (d, J = 4.2 Hz, 1H, Ar-H), 6.61 
(s, 1H, Ar-H), 6.35 (d, J = 4.2 Hz, 1H, Ar-H), 6.11 (s, 1H, 
Csp2-H), 5.33 (bs, 1H, NH), 3.96 (s, 2H), 4.05 (bd, J = 
15.1 Hz, 2H), 3.32 (t, J = 7.8 Hz, 2H), 3.12 (t, J = 15.1 Hz, 
2H), 2.80 (t, J = 7.8 Hz, 2H), 2.63 (m, 1H), 2.58 (s, 3H), 
2.27 (s, 3H), 1.96 (m, 2H), 1.73 (m, 2H). 19F NMR (376 
MHz, DMSO-d
6
): -145.675 (q, J
F-B
 = 31.4 Hz). 11B NMR 
(128 MHz, DMSO-d
6
): -1.7 (t, J
B-F
 = 31 Hz) HRMS: m/z 
(M + H) calcd. = 655.2508, found = 655.2562; m/z (M-19F) 
calcd. = 635.2446, found = 635.2492.
Cell lines
7KH 0<&1DPSOL¿HG QHXUREODVWRPD FHOO OLQH
UKF-NB-3 was established from a stage 4 neuroblastoma 
patient [44]. SHEP cells [45] were kindly provided by Dr. 
Angelika Eggert (Universität Duisburg-Essen, Germany). 
Neuroblastoma cell lines were adapted to growth in the 
presence of anti-cancer drugs by continuous exposure to 
increasing drug concentrations as described previously 
[19, 47, 49]. All neuroblastoma cell lines with acquired 
drug resistance were derived from the resistant cancer cell 
line (RCCL) collection. The corresponding IC50 values for 
the parental cells and their drug-resistant sub-lines were 
provided previously [19, 50]. All cells were propagated in 
IMDM supplemented with 10 % fetal calf serum (FCS), 
100 IU/ml penicillin, and 100 µg/ml streptomycin at 37°C. 
Cells were routinely tested for mycoplasma contamination 
DQGDXWKHQWLFDWHGE\VKRUWWDQGHPUHSHDWSUR¿OLQJ
UKF-NB-3 cells were transduced with lentiviral 
vectors encoding for ABCB1 (also known as MDR1 or 
P-glycoprotein) or ABCG2 (also known as BCRP) as 
described previously [50, 51] using the Lentiviral Gene 
Ontology (LeGO) vector technology [52] (www.lentigo-
vectors.de).
Viability assay
Cell viability was tested either by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dye reduction assay after 120 h incubation 
PRGL¿HGDVGHVFULEHGSUHYLRXVO\>@
Determination of ABCB1, ABCG2, and ABCC1 
expression
The ABC-transporters ABCB1, ABCC1, and 
$%&*ZHUHGHWHFWHGE\ÀRZF\WRPHWU\DVGHVFULEHG
SUHYLRXVO\>@XVLQJVSHFL¿FSULPDU\DQWLERGLHVDJDLQVW
ABCB1 (Alexis Biochemicals via AXXORA Deutschland, 
Lörrach, Germany), ABCC1, and ABCG2 (Kamiya 
Biomedical Company, Seattle, Washington) and secondary 
phycoerythrin(PE)-labelled goat anti-mouse antibody (PE, 
R&D Systems, Wiesbaden, Germany).
RNA interference experiments
Synthetic siRNAoligonucletides targeting 
CDK7, CDK9, ABCC1, or ABCB1 (ON-
TARGETplusSMARTpoolsiRNAs) were purchased from 
Dharmacon (Lafayette, CO, USA). The non-targeting 
siRNA ON-TARGETplusSMARTpool (Dharmacon) was 
used as negative control. Transfections were performed 
using the NeonTM Transfection System (Invitrogen, 
Darmstadt, Germany) according to the manufacturer´s 
protocol. UKF-NB-3 cells or UKF-NB-3rSNS-
032300nMFHOOVZHUHJURZQWRDERXWFRQÀXHQFH
trypsinized and 2 × 106 cells were re-suspended in 
200 µl of resuspension buffer containing 2.5 µM siRNA. 
Electroporation was performed in a pipette tip chamber 
ZLWK SUHYLRXVO\ RSWLPL]HG DGMXVWPHQWV YROWDJH 
width 20, 2 pulses). After electroporation, the cells were 
WUDQVIHUUHGLQWR¿EURQHFWLQȝJPO±FRDWHGZHOOSODWHV
containing pre-warmed IMDM plus 10% FCS.
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Western blot
Cells were lysed in Triton X-sample buffer and 
separated by SDS-PAGE. Proteins were detected using 
VSHFL¿F DQWLERGLHV GLUHFWHG DJDLQVW ȕDFWLQ %LR9LVLRQ
via BioCat GmbH, Heidelberg, Germany), ABCC1, 
ABCG2 (both from Santa Cruz Biotechnology, 
Heidelberg, Germany), ABCB1, XIAP, Mcl-1, CDK7, 
CDK9 (all from Cell Signaling via New England Biolabs, 
Frankfurt am Main, Germany), RNA polymerase II, Ser2-
phosphorylated RNA polymerase II, Ser5-phosphorylated 
RNA polymerase II (all from Abcam, Cambridge, 
UK), and survivin (R&D Systems, Wiesbaden, 
Germany). Protein bands were visualized by enhanced 
chemiluminescence using a commercially available kit 
7KHUPR6FLHQWL¿F6FKZHUWH*HUPDQ\
Flow cytometry
Cells were incubated with SNS-032-BODIPY for 45 
min at 37°C. Then, the cells were washed twice with PBS 
EHIRUHIUHVKPHGLXPZDVDGGHG7KHFHOOXODUÀXRUHVFHQFH
was analysed after a further 120 minutes using a FACS 
Canto (BD Biosciences, Heidelberg, Germany) using the 
FL1 channel. In verapamil-treated cells, verapamil was 
continuously present throughout the experiments including 
a pre-incubation period of 30 minutes at 37°C prior to the 
addition of SNS-032-BODIPY.
RNA synthesis assay
Detection of global RNA synthesis was performed 
as previously described [19] using the Click-iT® RNA 
HCS Assay (Invitrogen, Darmstadt, Germany).
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